
Opinion|Videos|July 29, 2024
Guiding Sequencing & Finding a Contemporary Regimen/ Approach to Treatment Post-Checkpoint Inhibition
Advertisement
Episodes in this series

- Please briefly mention the recent retrospective findings with cabo post-len + pembro – (
Haro-Silerio, et al. ASCO GU 2024. Abstract 433 ) = How do you approach treatment post-IO? - Please highlight recent data from the LITESPARK-011 trial(NCT04586231) evaluating belzutifan + lenvatinib vs cabozantinib in advanced RCC after anti-PD-L1 therapy (
Motzer, et al. Future Med, 2023
a. Please also briefly mention the significance of recent data from the phase 3 LITESPARK-005 trial (NCT04195750) assessing belzutifan versus everolimus in previously treated advanced RCC patients
i. Safety and Efficacy – (
ii. Patient reported outcomes – (
b.How does belzutifan fit into your treatment paradigm?
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


